Form 4: Allogene Therapeutics Director Joshua A. Kazam Acquires Stock Options
SEC Form 4
Director Joshua A. Kazam acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.
Summary
- On June 5, 2024, Joshua A. Kazam, a director of Allogene Therapeutics, Inc., acquired 191,082 stock options with an exercise price of $2.44.
- These options vest in 12 equal monthly installments and expire on June 5, 2034.
- Following the transaction, Kazam directly owns 191,082 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. It doesn't inherently indicate positive or negative performance, but rather a standard compensation practice.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard Form 4 filing, reflecting a transaction by a company insider. Option grants are a common form of compensation in the biotechnology industry.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of the stock option transaction. |
| 06/05/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.